SCHEMBL4589696

SCHEMBL4589696

Cc1ccc(CC#N)c(C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 3/20 0.35
HTT P42858 2/20 0.35
TKT P29401 1/20 0.35
RAB9A P51151 2/20 0.34
CCR1 P32246 1/20 0.34
CCR5 P51681 1/20 0.34
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
MAPT P10636 1/20 0.32
NPC1 O15118 1/20 0.31
GAA P10253 1/20 0.31
ABCB1 P08183 1/20 0.31
ABCG2 Q9UNQ0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19284141 0.80 ATP4A (0.35) ALDH1A1ATP4AATP4BMEN1KMT2A
SCHEMBL25786511 0.80 EGLN2 (0.39) ALDH1A1KDM4EHTTTKTATP4A
SCHEMBL20565709 0.80 KMT2A (0.36) ALDH1A1KDM4ETKTRAB9ACCR1
SCHEMBL30034016 0.80 KMT2A (0.36) ALDH1A1KDM4ETKTRAB9ACCR1
SCHEMBL32680194 0.77 NNMT (0.41) TDP1KMT2ACYP1A2
SCHEMBL14051365 0.77 NNMT (0.41) TDP1KMT2ACYP1A2
SCHEMBL24168466 0.76 RXRA (0.34) HTTTKTL3MBTL1TDP1SMN1; SMN2
SCHEMBL25786512 0.76 KDM4E (0.39) KDM4ETKTRAB9ANPC1GAA
SCHEMBL4165768 0.76 KDM4E (0.34) ALDH1A1KDM4EHTTRAB9AATP4A
SCHEMBL7573152 0.73 CCR1 (0.40) ALDH1A1KDM4ERAB9ACCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4524146-A1 MRNA CAP ANALOG AND METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING MRNA, AND KIT YAMASA CORPORATION (JP) 2025-03-19 EP disclosed
US-12202848-B2 Phosphoramidite activator FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2025-01-21 US disclosed
US-20240166674-A1 PHOSPHORAMIDITE ACTIVATOR FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2024-05-23 US disclosed
CN-114555617-B Phosphoramidite activators 富士胶片和光纯药株式会社 2024-03-08 CN disclosed
EP-4047004-B1 PHOSPHORAMIDITE ACTIVATOR FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2024-03-06 EP disclosed
WO-2023219114-A1 MRNA CAP ANALOG AND METHOD FOR PRODUCING SAME, METHOD FOR PRODUCING MRNA, AND KIT ヤマサ醤油株式会社 2023-11-16 WO disclosed
WO-2022255273-A1 LIGAND-BOUND NUCLEIC ACID COMPLEX レナセラピューティクス株式会社 2022-12-08 WO disclosed
EP-4047004-A1 PHOSPHORAMIDITE ACTIVATOR FUJIFILM Wako Pure Chemical Corporation (JP) 2022-08-24 EP disclosed
US-20200054630-A1 BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION MINDIMMUNE THERAPEUTICS, INC. 2020-02-20 US disclosed
US-10238654-B2 Benzamides-containing compounds and their use in the treatment of epilepsy MINDIMMUNE THERAPEUTICS, INC. (US) 2019-03-26 US disclosed
EP-2906546-B1 BENZAMIDES H LUNDBECK AS (DK) 2018-01-10 EP disclosed
US-20170202836-A1 Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy H. LUNDBECK A/S (DK) 2017-07-20 US disclosed
US-9649308-B2 Benzamide-containing compounds and their use in the treatment of pain H. LUNDBECK A/S (DK) 2017-05-16 US disclosed
US-20150283134-A1 Benzamides MINDIMMUNE THERAPEUTICS, INC. 2015-10-08 US disclosed
CN-104884445-A Benzamides LUNDBECK & CO AS H 2015-09-02 CN disclosed
EP-2906546-A1 BENZAMIDES H. Lundbeck A/S (DK) 2015-08-19 EP disclosed
US-9102591-B2 Benzamides H. LUNDBECK A/S (DK) 2015-08-11 US disclosed
WO-2014057078-A1 BENZAMIDES H. LUNDBECK A/S (DK) 2014-04-17 WO disclosed
US-20140107340-A1 Benzamides H. LUNDBECK A/S (DK) 2014-04-17 US disclosed
US-20080108557-A1 Modified Proteins NOVO NORDISK HEALTHCARE A/G (CH) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200054630-A1 BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION P2RX5, P2RX7, P2RX2 ALDH1A1 637/4885KDM4E 1502/4885HTT 2050/4885
US-20240166674-A1 PHOSPHORAMIDITE ACTIVATOR ITPA, INPP5D, INPP5B ALDH1A1 3801/4885KDM4E 2521/4885HTT 1740/4885
US-20140107340-A1 Benzamides P2RX7, TRPV1, P2RX5 ALDH1A1 1424/4885KDM4E 2338/4885HTT 3505/4885
US-20080108557-A1 Modified Proteins PTMS, DNPEP, STT3A ALDH1A1 3891/4885KDM4E 3955/4885HTT 2769/4885
US-12202848-B2 Phosphoramidite activator ITPA, INPP5D, INPP5B ALDH1A1 3801/4885KDM4E 2521/4885HTT 1740/4885
US-10238654-B2 Benzamides-containing compounds and their use in the treatment of epilepsy P2RX5, P2RX7, P2RX6 ALDH1A1 767/4885KDM4E 1075/4885HTT 3383/4885
US-20170202836-A1 Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy P2RX5, P2RX7, P2RX6 ALDH1A1 767/4885KDM4E 1075/4885HTT 3383/4885
US-20150283134-A1 Benzamides P2RX7, TRPV1, P2RX5 ALDH1A1 1424/4885KDM4E 2338/4885HTT 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.